BioCardia CFO awarded 60,483 restricted shares

BioCardia, Inc. reported that Chief Financial Officer David McClung acquired 60,483 shares of common stock through a grant of restricted stock units (RSUs) awarded as compensation in lieu of cash.

Rhea-AI Filing Summary

BioCardia, Inc. reported that Chief Financial Officer David McClung acquired 60,483 shares of common stock through a grant of restricted stock units (RSUs) awarded as compensation in lieu of cash. Each RSU represents one share of common stock, and 100% of the RSUs vested on June 29, 2026. Following this award, McClung directly owns 137,370 shares of BioCardia common stock. This is a compensation-related equity grant rather than an open-market share purchase.

Insider Trade Summary

Grant/Award: 60,483 shares

Grant/Award 1 txn

Insider McClung David

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	60,483	$1.20	$73K

Holdings After Transaction: Common Stock — 137,370 shares (Direct)

Footnotes (1)

1. F1. The reported securities represent restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock awarded as compensation in lieu of cash. 100% of the RSUs vested on June 29, 2026.

Key Figures

RSU grant size: 60,483 shares RSU grant price: $1.20 per share Shares owned after grant: 137,370 shares

3 metrics

RSU grant size 60,483 shares Restricted stock units awarded to CFO on June 29, 2026

RSU grant price $1.20 per share Reported value per share for 60,483 RSUs

Shares owned after grant 137,370 shares CFO’s direct BioCardia common stock holdings following the RSU vesting

Key Terms

restricted stock units ("RSUs"), compensation in lieu of cash, Common Stock

3 terms

restricted stock units ("RSUs") financial

"The reported securities represent restricted stock units ("RSUs"), each of which represents a contingent right..."

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

compensation in lieu of cash financial

"common stock awarded as compensation in lieu of cash. 100% of the RSUs vested on June 29, 2026."

Common Stock financial

"security_title": "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did BioCardia (BCDA) report for its CFO?

BioCardia reported that CFO David McClung received a grant of 60,483 restricted stock units, each representing one share of common stock. The award was given as compensation in lieu of cash and fully vested on June 29, 2026, increasing his direct holdings.

How many BioCardia (BCDA) shares does the CFO hold after this Form 4?

After the reported RSU grant, CFO David McClung directly owns 137,370 shares of BioCardia common stock. This total reflects the addition of 60,483 shares delivered through vested restricted stock units that were granted as stock-based compensation instead of cash.

Was the BioCardia (BCDA) CFO’s transaction a market purchase or a stock grant?

The transaction was a stock grant, not a market purchase. David McClung acquired 60,483 shares via restricted stock units awarded as compensation in lieu of cash, with all units vesting on June 29, 2026, rather than buying shares in the open market.

At what price were the BioCardia (BCDA) RSUs for the CFO valued?

The restricted stock units granted to CFO David McClung were reported at a value of $1.20 per share for 60,483 shares. This valuation applies to the RSU award that vested in full on June 29, 2026, increasing his equity stake in BioCardia.

What does the RSU vesting schedule look like for the BioCardia (BCDA) CFO grant?

The RSU award to CFO David McClung vested 100% on June 29, 2026. This means all 60,483 restricted stock units converted into an equal number of BioCardia common shares on that date, with no remaining unvested portion from this particular grant.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/01/2026 - 07:37 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

McClung David

(Last) (First) (Middle)

C/O BIOCARDIA, INC.

320 SOQUEL WAY

(Street)

SUNNYVALE CALIFORNIA 94085

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BioCardia, Inc. [ BCDA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/29/2026		A		60,483(1)	A	$1.2(1)	137,370	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The reported securities represent restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock awarded as compensation in lieu of cash. 100% of the RSUs vested on June 29, 2026.

	/s/ David McClung	07/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)